Entrectinib and larotrectinib have been approved to treat tumors with fusions in the neurotrophic tropomyosin receptor kinase (NTRK) gene – irrespective of the tumor’s site of origin.

These drugs are the second and third agents, overall, to have a tissue-agnostic indication approved by the FDA.

The first was pembrolizumab, an immunotherapy agent, indicated for tumors with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors in 2017.

Have we finally reached the point where tumor biology has become a more important consideration than site of origin?